BRD4?Inhibitor-27

CAS No. 930039-92-2

BRD4?Inhibitor-27( —— )

Catalog No. M37196 CAS No. 930039-92-2

BRD4 Inhibitor-27 is a potent BRD4 inhibitor that inhibits BRD4 BD1 and BRD4 BD2 with IC50s of 9.6 and 11.3 μM, respectively.BRD4 Inhibitor-27 has anticancer activity and can be used for breast cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 296 Get Quote
5MG 459 Get Quote
10MG 657 Get Quote
25MG 994 Get Quote
50MG 1371 Get Quote
100MG 1773 Get Quote
500MG 3537 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BRD4?Inhibitor-27
  • Note
    Research use only, not for human use.
  • Brief Description
    BRD4 Inhibitor-27 is a potent BRD4 inhibitor that inhibits BRD4 BD1 and BRD4 BD2 with IC50s of 9.6 and 11.3 μM, respectively.BRD4 Inhibitor-27 has anticancer activity and can be used for breast cancer research.
  • Description
    BRD4 Inhibitor-27 (compound 6) is a BRD4 inhibitor with IC50 of 9.6 and 11.3 μM forBRD4 BD1 andBRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    930039-92-2
  • Formula Weight
    346.31
  • Molecular Formula
    C16H13F3N6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    FC(F)(F)C1=NN=C2C=CC(NCCC3=CNC4=C3C=CC=C4)=NN12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kim JH, et al. Crystal structure of [1,2,4] triazolo[4,3- b ]pyridazine derivatives as BRD4 bromodomain inhibitors and structure–activity relationship study . Sci Rep 13, 10805 (2023).
molnova catalog
related products
  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.

  • FHD-286

    FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.

  • WAY-309060

    WAY-309060 is a BRD4 small molecule inhibitor with antitumor activity.